AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03764683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Suvorexant (Belsomra)
Description: Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
Study NCT03764683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
Study NCT03764683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
Study NCT02413047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
Study NCT02413047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mercaptopurine
Description: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Study NCT02413047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
Study NCT01549977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablets
Study NCT01549977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching tablets
Study NCT04682535 — intervention group
Intervention type: OTHER
Intervention: Social relationships
Description: Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
Study NCT02933502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS topical product
Description: treatment daily for 28 days
Study NCT03182907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
Study NCT03182907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
Study NCT03182907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment (ABD)
Description: ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study NCT03182907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibacterial drug treatment (ABD)
Description: ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study NCT02685904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENIA11
Study NCT02685904 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03043651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Sustained-release oral tablets for TID administration
Study NCT01652131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tetrastarch (130/0.4)
Study NCT03651609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple decompression of the ulnar nerve
Description: Surgical HUA release 2-3 cm distal to medial epicondyle with minimal-incision technique .
Study NCT03651609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
Study NCT03651609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
Study NCT02428205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Participant will receive Propranolol prior to each EIBI session
Study NCT02428205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive placebo prior to each EIBI session
Study NCT05491434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: One líquid brick every day during 3 weeks
Study NCT00360724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine (Cymbalta)
Description: duloxetine medication up to dose of 120 mg/day
Study NCT00360724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Cymbalta)
Description: duloxetine medication up to dose of 120 mg/day
Study NCT03964402 — intervention group
Intervention type: DRUG
Intervention: intervention treatment
Description: intervention treatment (any)
Study NCT01041521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
Study NCT01540669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose, low dose
Description: 4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
Study NCT01540669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose, medium dose
Description: 8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
Study NCT01540669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose, high dose
Description: 12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
Study NCT01540669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
Study NCT02847104 — intervention group
Intervention type: OTHER
Intervention: dynamic insulin protocol
Description: Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
Study NCT02847104 — intervention group
Intervention type: OTHER
Intervention: static insulin protocol
Description: Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
Study NCT02721095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KCl plus 0.9%NaCl
Description: comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
Study NCT02721095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KCl plus 0.45%NaCl
Description: comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
Study NCT02673502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: simple carbohydrate drink
Description: Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
Study NCT02673502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: complex carbohydrate drink
Description: Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
Study NCT00384332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orally-disintegrating olanzapine
Description: 5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
Study NCT00384332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regular olanzapine
Description: 5-20 mg. olanzapine daily for approximately 8 weeks.
Study NCT02653937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tsumura's shigyakusan
Description: Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne
Study NCT01221493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryo biopsy
Description: Cryoprobe, Erbe Company
Study NCT05021575 — intervention group
Intervention type: OTHER
Intervention: Data collection on outpatient care
Description: Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~1. data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~2. data were collected from CVD prevention program~3. data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded.
Study NCT05021575 — intervention group
Intervention type: OTHER
Intervention: Data collection on hospitalisation
Description: Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code.
Study NCT01218555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
Study NCT03270098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
Study NCT01599273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subconjunctival triamcinolone injection
Description: Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
Study NCT03170973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
Study NCT01315704 — intervention group
Intervention type: DRUG
Intervention: Drug intervention
Description: before-after interventional (anti-dementia drugs and/or vitamin D) study
Study NCT03829748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent aspiration
Description: Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
Study NCT02251795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02251795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Study NCT02251795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02251795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Study NCT02251795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: single dose on day 2
Study NCT02251795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: single dose on day 2
Study NCT03270098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Toning Exercise
Description: Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
Study NCT02034188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Study NCT01739972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
Study NCT01739972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desiccated thyroid extract
Description: Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
Study NCT02399111 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prevena Incision Management System
Description: The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
Study NCT01285882 — intervention group
Intervention type: OTHER
Intervention: Representations
Description: 1. A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~2. To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~   * 1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~  * 2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~3. Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation.
Study NCT01052714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Balance
Description: Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
Study NCT01052714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Balance
Description: Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
Study NCT05021575 — intervention group
Intervention type: OTHER
Intervention: Data collection on cardiovascular mortality
Description: Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
Study NCT05021575 — intervention group
Intervention type: OTHER
Intervention: Data collection of patients presenting to the tertiary care centre with acute coronary syndrome
Description: Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
Study NCT04697732 — intervention group
Intervention type: OTHER
Intervention: General anesthesia
Description: Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
Study NCT01959438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium selenite (Introselen)
Description: Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
Study NCT01959438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium selenite
Description: Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
Study NCT03144986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Insula-coil rTMS
Description: Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
Study NCT00820417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab/Gefitinib combination and/or monotherapy
Study NCT01962870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
Study NCT01962870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00889642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine
Description: Active- 10.5% Lidocaine/0.179% Epinephrine
Study NCT00889642 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoretic Drug Delivery System with Epinephrine
Description: Placebo- 0.179% Epinephrine
Study NCT00379067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin OCAS
Description: Adrenoceptor antagonist
Study NCT00379067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01511081 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT (stereotactic body radiotherapy)
Description: 50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.